Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nesvacumab + Aflibercept in Neovascular AMD
NCT02713204Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2016
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nesvacumab in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Started Mar 2016; status: completed.
02
Drugs
nesvacumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02713204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02713204.